Chilton RJ - Search Results

1

The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study.

Ard JD, Neeland IJ, Rothberg AE, Chilton RJ, de Luis D, Cohen SS, Johansen OE. Ard JD, et al. Among authors: chilton rj. Diabetes Obes Metab. 2024 Mar;26(3):950-960. doi: 10.1111/dom.15392. Epub 2023 Dec 11. Diabetes Obes Metab. 2024. PMID: 38073426 Clinical Trial.

2

Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects.

Chen X, Tripathy D, Chilton R, Hansis-Diarte A, Salehi M, Solis-Herrera C, Cersosimo E, DeFronzo RA. Chen X, et al. Diabetes. 2024 Jun 1;73(6):896-902. doi: 10.2337/db23-0457. Diabetes. 2024. PMID: 38512770 Clinical Trial.

3

Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes.

Krämer BK, Hauske SJ, Chilton R, Mann JFE, Gullestad L, Fitchett D, Mattheus M, Steubl D, Wanner C. Krämer BK, et al. J Diabetes Complications. 2023 Sep;37(9):108588. doi: 10.1016/j.jdiacomp.2023.108588. Epub 2023 Aug 17. J Diabetes Complications. 2023. PMID: 37633072 Free article. Clinical Trial.

4

Deciphering the connection: Diabetes, pericyte dysfunction, and their impact on cardiovascular health.

Chilton R, Iranpour EI, Bloomgarden Z. Chilton R, et al. J Diabetes. 2024 Feb;16(2):e13539. doi: 10.1111/1753-0407.13539. J Diabetes. 2024. PMID: 38403297 Free PMC article. No abstract available.

5

Cardioprotective Potential of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Cancer Treated With Anthracyclines: An Observational Study.

Fath AR, Aglan M, Aglan A, Chilton RJ, Trakhtenbroit A, Al-Shammary OA, Oppong-Nkrumah O, Lenihan DJ, Dent SF, Otchere P. Fath AR, et al. Among authors: chilton rj. Am J Cardiol. 2024 Apr 30;222:175-182. doi: 10.1016/j.amjcard.2024.04.032. Online ahead of print. Am J Cardiol. 2024. PMID: 38692401

6

Mineralocorticoid receptor antagonists in cardiovascular translational biology.

Chilton RJ, Silva-Cardoso J. Chilton RJ, et al. Cardiovasc Endocrinol Metab. 2023 Aug 21;12(3):e0289. doi: 10.1097/XCE.0000000000000289. eCollection 2023 Sep. Cardiovasc Endocrinol Metab. 2023. PMID: 37614245 Free PMC article. Review.

7

Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes.

Moody AJ, Molina-Wilkins M, Clarke GD, Merovci A, Solis-Herrera C, Cersosimo E, Chilton RJ, Iozzo P, Gastaldelli A, Abdul-Ghani M, DeFronzo RA. Moody AJ, et al. Among authors: chilton rj. Diabetes Obes Metab. 2023 Feb;25(2):426-434. doi: 10.1111/dom.14885. Epub 2022 Nov 4. Diabetes Obes Metab. 2023. PMID: 36204991 Free PMC article.

8

SGLT2 inhibitors: a narrative review of efficacy and safety.

Nelinson DS, Sosa JM, Chilton RJ. Nelinson DS, et al. Among authors: chilton rj. J Osteopath Med. 2021 Feb 1;121(2):229-239. doi: 10.1515/jom-2020-0153. J Osteopath Med. 2021. PMID: 33567084 Free article. Review.

9

Beyond the myocardium: Sodium-glucose co-transporter-2 inhibitors in heart failure.

Chilton RJ. Chilton RJ. Diabetes Obes Metab. 2021 May;23(5):1215-1218. doi: 10.1111/dom.14320. Epub 2021 Feb 26. Diabetes Obes Metab. 2021. PMID: 33464709 No abstract available.

10

The role of rivaroxaban for patients with atherosclerotic vascular disease in the modern era.

Vogt JC, Manning PG, Sheikh O, Aronow HD, Chilton RJ, Cigarroa JE. Vogt JC, et al. Among authors: chilton rj. Catheter Cardiovasc Interv. 2021 May 1;97(6):1221-1229. doi: 10.1002/ccd.29089. Epub 2020 Jul 8. Catheter Cardiovasc Interv. 2021. PMID: 32638540 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

51 results

Search Page